Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 49 | 2020 | 348 | 5.890 |
Why?
|
| Pancreas Transplantation | 16 | 2018 | 80 | 3.170 |
Why?
|
| Tissue Donors | 27 | 2018 | 167 | 2.080 |
Why?
|
| Graft Rejection | 18 | 2018 | 149 | 1.970 |
Why?
|
| Graft Survival | 27 | 2020 | 228 | 1.800 |
Why?
|
| Immunosuppressive Agents | 13 | 2016 | 167 | 1.490 |
Why?
|
| Islets of Langerhans | 7 | 2017 | 74 | 1.400 |
Why?
|
| Islets of Langerhans Transplantation | 6 | 2017 | 40 | 1.300 |
Why?
|
| Delayed Graft Function | 9 | 2020 | 33 | 1.270 |
Why?
|
| Tissue and Organ Procurement | 12 | 2018 | 69 | 1.150 |
Why?
|
| Antilymphocyte Serum | 5 | 2014 | 17 | 0.980 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 366 | 0.940 |
Why?
|
| Immunosuppression | 5 | 2014 | 80 | 0.870 |
Why?
|
| Kidney Failure, Chronic | 12 | 2018 | 518 | 0.800 |
Why?
|
| Pancreas | 6 | 2017 | 79 | 0.760 |
Why?
|
| Donor Selection | 4 | 2019 | 31 | 0.740 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 109 | 0.730 |
Why?
|
| Extracorporeal Circulation | 2 | 2011 | 11 | 0.720 |
Why?
|
| Antibodies, Neoplasm | 3 | 2009 | 12 | 0.700 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 192 | 0.680 |
Why?
|
| Humans | 64 | 2020 | 29093 | 0.640 |
Why?
|
| Antibodies, Monoclonal | 4 | 2009 | 196 | 0.620 |
Why?
|
| Living Donors | 3 | 2015 | 51 | 0.620 |
Why?
|
| Drug Compounding | 3 | 2017 | 36 | 0.600 |
Why?
|
| Regenerative Medicine | 6 | 2015 | 187 | 0.580 |
Why?
|
| Middle Aged | 34 | 2020 | 10829 | 0.560 |
Why?
|
| Kidney | 9 | 2020 | 485 | 0.530 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 53 | 0.530 |
Why?
|
| Retrospective Studies | 26 | 2019 | 3111 | 0.530 |
Why?
|
| Uremia | 1 | 2015 | 9 | 0.520 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 11 | 0.510 |
Why?
|
| Female | 37 | 2020 | 18164 | 0.470 |
Why?
|
| Adult | 28 | 2020 | 8420 | 0.470 |
Why?
|
| Biopolymers | 1 | 2013 | 4 | 0.450 |
Why?
|
| Tissue Scaffolds | 7 | 2016 | 386 | 0.450 |
Why?
|
| Artificial Organs | 1 | 2013 | 12 | 0.450 |
Why?
|
| Nephrectomy | 5 | 2019 | 114 | 0.430 |
Why?
|
| Male | 36 | 2020 | 17807 | 0.430 |
Why?
|
| Extracellular Matrix | 4 | 2016 | 226 | 0.420 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2009 | 35 | 0.420 |
Why?
|
| Thrombosis | 1 | 2012 | 60 | 0.410 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 70 | 0.400 |
Why?
|
| Cadaver | 13 | 2018 | 143 | 0.400 |
Why?
|
| Thrombectomy | 1 | 2012 | 58 | 0.400 |
Why?
|
| Heart Arrest | 1 | 2011 | 39 | 0.390 |
Why?
|
| Bioengineering | 4 | 2015 | 67 | 0.390 |
Why?
|
| Anticoagulants | 1 | 2012 | 120 | 0.390 |
Why?
|
| Regeneration | 5 | 2016 | 167 | 0.360 |
Why?
|
| Animals | 15 | 2017 | 7297 | 0.350 |
Why?
|
| Pancreatectomy | 1 | 2008 | 29 | 0.330 |
Why?
|
| C-Peptide | 3 | 2018 | 25 | 0.320 |
Why?
|
| Young Adult | 8 | 2019 | 2402 | 0.320 |
Why?
|
| Survival Rate | 10 | 2018 | 795 | 0.300 |
Why?
|
| Alginates | 4 | 2017 | 49 | 0.290 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 79 | 0.290 |
Why?
|
| Treatment Outcome | 15 | 2017 | 3099 | 0.280 |
Why?
|
| Adolescent | 8 | 2019 | 3254 | 0.270 |
Why?
|
| Postoperative Complications | 5 | 2018 | 670 | 0.270 |
Why?
|
| Omentum | 2 | 2017 | 26 | 0.270 |
Why?
|
| Blood Group Incompatibility | 2 | 2016 | 11 | 0.270 |
Why?
|
| ABO Blood-Group System | 2 | 2016 | 19 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2017 | 180 | 0.260 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2017 | 51 | 0.260 |
Why?
|
| Cold Ischemia | 2 | 2018 | 7 | 0.260 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 231 | 0.260 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 2108 | 0.260 |
Why?
|
| Aged | 18 | 2019 | 9487 | 0.240 |
Why?
|
| Patient Selection | 5 | 2018 | 257 | 0.230 |
Why?
|
| Reoperation | 3 | 2019 | 203 | 0.230 |
Why?
|
| History, 20th Century | 2 | 2016 | 68 | 0.220 |
Why?
|
| Insulin | 4 | 2018 | 346 | 0.210 |
Why?
|
| Rabbits | 2 | 2014 | 185 | 0.210 |
Why?
|
| Tissue Engineering | 4 | 2016 | 608 | 0.200 |
Why?
|
| Risk Factors | 9 | 2018 | 3531 | 0.200 |
Why?
|
| Perfusion | 3 | 2013 | 64 | 0.180 |
Why?
|
| Prognosis | 7 | 2018 | 1362 | 0.180 |
Why?
|
| Time Factors | 9 | 2016 | 2001 | 0.180 |
Why?
|
| RNA | 1 | 2020 | 88 | 0.170 |
Why?
|
| Hexuronic Acids | 3 | 2014 | 31 | 0.170 |
Why?
|
| Glucuronic Acid | 3 | 2014 | 31 | 0.170 |
Why?
|
| Child, Preschool | 6 | 2019 | 1167 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2018 | 2019 | 0.170 |
Why?
|
| Blood Glucose | 3 | 2017 | 466 | 0.170 |
Why?
|
| Angiography | 1 | 2019 | 75 | 0.170 |
Why?
|
| Mycophenolic Acid | 3 | 2008 | 28 | 0.170 |
Why?
|
| Endarterectomy | 1 | 2018 | 7 | 0.170 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 320 | 0.160 |
Why?
|
| Death | 2 | 2009 | 41 | 0.160 |
Why?
|
| Renal Artery | 1 | 2018 | 43 | 0.160 |
Why?
|
| North Carolina | 6 | 2018 | 1423 | 0.160 |
Why?
|
| Gastrointestinal Tract | 3 | 2012 | 29 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 436 | 0.160 |
Why?
|
| Bioartificial Organs | 1 | 2017 | 25 | 0.160 |
Why?
|
| Insulin-Secreting Cells | 1 | 2017 | 53 | 0.150 |
Why?
|
| Incidence | 4 | 2018 | 1119 | 0.150 |
Why?
|
| Oxygen | 1 | 2017 | 139 | 0.150 |
Why?
|
| Apolipoproteins | 2 | 2016 | 196 | 0.150 |
Why?
|
| Cells, Immobilized | 1 | 2017 | 23 | 0.150 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 247 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 2 | 2014 | 25 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 59 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 29 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 48 | 0.140 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
| United States | 5 | 2017 | 3630 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2016 | 190 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1218 | 0.130 |
Why?
|
| Radiography, Interventional | 1 | 2014 | 35 | 0.130 |
Why?
|
| Age Factors | 6 | 2019 | 1108 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 176 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2014 | 14 | 0.120 |
Why?
|
| Immunocompetence | 1 | 2014 | 12 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 871 | 0.120 |
Why?
|
| Child | 4 | 2019 | 2219 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2014 | 35 | 0.120 |
Why?
|
| Isoantibodies | 1 | 2014 | 10 | 0.120 |
Why?
|
| Portal Vein | 1 | 2013 | 16 | 0.120 |
Why?
|
| Drainage | 1 | 2013 | 49 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 287 | 0.120 |
Why?
|
| Pancreas, Artificial | 1 | 2013 | 4 | 0.120 |
Why?
|
| Transplantation, Homologous | 3 | 2009 | 113 | 0.120 |
Why?
|
| Creatinine | 5 | 2016 | 174 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2013 | 74 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2013 | 62 | 0.110 |
Why?
|
| Warfarin | 1 | 2012 | 30 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 38 | 0.100 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 102 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2014 | 239 | 0.100 |
Why?
|
| Azathioprine | 1 | 2011 | 8 | 0.100 |
Why?
|
| Aspirin | 1 | 2012 | 61 | 0.100 |
Why?
|
| Gout | 1 | 2011 | 14 | 0.100 |
Why?
|
| Thiazoles | 1 | 2011 | 32 | 0.100 |
Why?
|
| Heparin | 1 | 2012 | 75 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2011 | 1687 | 0.100 |
Why?
|
| African Americans | 2 | 2016 | 1373 | 0.100 |
Why?
|
| Warm Ischemia | 1 | 2011 | 8 | 0.100 |
Why?
|
| General Surgery | 1 | 2012 | 81 | 0.100 |
Why?
|
| Length of Stay | 2 | 2014 | 292 | 0.100 |
Why?
|
| Acute Disease | 1 | 2012 | 239 | 0.100 |
Why?
|
| Organ Preservation | 2 | 2009 | 13 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1079 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2013 | 440 | 0.100 |
Why?
|
| Tacrolimus | 2 | 2008 | 44 | 0.090 |
Why?
|
| Inflammation | 2 | 2012 | 507 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 159 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2010 | 69 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2010 | 65 | 0.090 |
Why?
|
| Infant | 4 | 2019 | 969 | 0.090 |
Why?
|
| Steroids | 1 | 2009 | 36 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 114 | 0.090 |
Why?
|
| Leukopenia | 1 | 2008 | 7 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 16 | 0.080 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2008 | 21 | 0.080 |
Why?
|
| Ganciclovir | 2 | 2008 | 14 | 0.080 |
Why?
|
| Mycoplasma hominis | 1 | 2005 | 1 | 0.070 |
Why?
|
| Cell Survival | 2 | 2017 | 272 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2015 | 1131 | 0.060 |
Why?
|
| Arthritis, Infectious | 1 | 2005 | 21 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 293 | 0.060 |
Why?
|
| Hypertension | 1 | 2011 | 906 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2016 | 447 | 0.060 |
Why?
|
| Transplantation Immunology | 2 | 2015 | 27 | 0.060 |
Why?
|
| Phenotype | 2 | 2016 | 629 | 0.060 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 203 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 709 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 2 | 2014 | 106 | 0.060 |
Why?
|
| Brain Death | 2 | 2014 | 27 | 0.060 |
Why?
|
| Cytosine | 1 | 2002 | 9 | 0.050 |
Why?
|
| BK Virus | 1 | 2002 | 7 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2019 | 440 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 150 | 0.050 |
Why?
|
| African Continental Ancestry Group | 1 | 2002 | 350 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2014 | 91 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2002 | 52 | 0.050 |
Why?
|
| Liver Transplantation | 2 | 2012 | 111 | 0.050 |
Why?
|
| Antiviral Agents | 3 | 2008 | 100 | 0.050 |
Why?
|
| Intestines | 2 | 2010 | 54 | 0.050 |
Why?
|
| Registries | 2 | 2016 | 278 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3717 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 637 | 0.040 |
Why?
|
| Microspheres | 1 | 2017 | 37 | 0.040 |
Why?
|
| Capsules | 1 | 2017 | 14 | 0.040 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2016 | 9 | 0.040 |
Why?
|
| Organogenesis | 1 | 2016 | 15 | 0.040 |
Why?
|
| Social Support | 1 | 2017 | 163 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2007 | 30 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 31 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
| Metaplasia | 1 | 2014 | 20 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 45 | 0.030 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 15 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 15 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2014 | 64 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 84 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 159 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2014 | 116 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 735 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 110 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 241 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 31 | 0.030 |
Why?
|
| Detergents | 1 | 2013 | 17 | 0.030 |
Why?
|
| Chickens | 1 | 2013 | 40 | 0.030 |
Why?
|
| Pressure | 1 | 2013 | 54 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2013 | 44 | 0.030 |
Why?
|
| Maryland | 2 | 2002 | 26 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 1604 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 572 | 0.030 |
Why?
|
| Skin, Artificial | 1 | 2012 | 31 | 0.030 |
Why?
|
| Larynx | 1 | 2012 | 19 | 0.030 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 22 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 30 | 0.030 |
Why?
|
| Swine | 1 | 2012 | 201 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2012 | 63 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2011 | 4 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 78 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2011 | 80 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 519 | 0.030 |
Why?
|
| Corneal Transplantation | 1 | 2010 | 13 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 217 | 0.020 |
Why?
|
| Transplants | 1 | 2010 | 22 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 182 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2368 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2012 | 210 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 573 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 55 | 0.020 |
Why?
|
| Solutions | 1 | 2009 | 26 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 161 | 0.020 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2009 | 6 | 0.020 |
Why?
|
| Asphyxia | 1 | 2009 | 6 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 250 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 816 | 0.020 |
Why?
|
| Infarction | 1 | 2009 | 5 | 0.020 |
Why?
|
| Suicide | 1 | 2009 | 17 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 21 | 0.020 |
Why?
|
| Ischemia | 1 | 2009 | 92 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 38 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 464 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 292 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 37 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 464 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2007 | 42 | 0.020 |
Why?
|
| Body Size | 1 | 2006 | 31 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 220 | 0.020 |
Why?
|
| Heart Failure | 1 | 2012 | 568 | 0.020 |
Why?
|
| Nephrons | 1 | 2006 | 10 | 0.020 |
Why?
|
| Ofloxacin | 1 | 2005 | 2 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2006 | 134 | 0.020 |
Why?
|
| Hip | 1 | 2005 | 13 | 0.020 |
Why?
|
| Edema | 1 | 2005 | 30 | 0.020 |
Why?
|
| Doxycycline | 1 | 2005 | 25 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 859 | 0.020 |
Why?
|
| Prednisone | 1 | 2005 | 43 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 43 | 0.020 |
Why?
|
| Pelvis | 1 | 2005 | 61 | 0.020 |
Why?
|
| Radiography | 1 | 2005 | 353 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 546 | 0.010 |
Why?
|
| Sirolimus | 1 | 2003 | 35 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 150 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 129 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1379 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 104 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 246 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 290 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 2002 | 35 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2002 | 1305 | 0.010 |
Why?
|